74 related articles for article (PubMed ID: 8603814)
1. Modulation of lymphokine-activated killer cell-mediated cytotoxicity by estradiol and tamoxifen.
Baral E; Nagy E; Berczi I
Int J Cancer; 1996 Apr; 66(2):214-8. PubMed ID: 8603814
[TBL] [Abstract][Full Text] [Related]
2. Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol.
Baral E; Nagy E; Berczi I
Cancer; 1995 Jan; 75(2):591-9. PubMed ID: 7812928
[TBL] [Abstract][Full Text] [Related]
3. Target cells are sensitized for cytotoxic T-lymphocyte-mediated destruction by estradiol and tamoxifen.
Baral E; Nagy E; Berczi I
Int J Cancer; 1994 Jul; 58(1):64-8. PubMed ID: 8014017
[TBL] [Abstract][Full Text] [Related]
4. Anti-estrogens enhance the therapeutic effect of lymphokine-activated killer cells on the P815 murine mastocytoma.
Baral E; Nagy E; Kangas L; Berczi I
Int J Cancer; 1996 Aug; 67(4):580-5. PubMed ID: 8759619
[TBL] [Abstract][Full Text] [Related]
5. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
Baral E; Nagy E; Kangas L; Berczi I
Anticancer Res; 1997; 17(5A):3653-8. PubMed ID: 9413218
[TBL] [Abstract][Full Text] [Related]
6. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells.
Baral E; Nagy E; Krepart GV; Lotocki RJ; Unruh HW; Berczi I
Anticancer Res; 2000; 20(3B):2027-31. PubMed ID: 10928146
[TBL] [Abstract][Full Text] [Related]
7. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.
Nagy E; Baral E; Kangas L; Berczi I
Anticancer Res; 1997; 17(2A):1083-8. PubMed ID: 9137453
[TBL] [Abstract][Full Text] [Related]
8. Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms.
Bean P; Mazumder A
Immunobiology; 1992 Jun; 185(1):63-77. PubMed ID: 1398742
[TBL] [Abstract][Full Text] [Related]
9. Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells.
Albertini MR; Gibson DF; Robinson SP; Howard SP; Tans KJ; Lindstrom MJ; Robinson RR; Tormey DC; Jordan VC; Sondel PM
J Immunother (1991); 1992 Jan; 11(1):30-9. PubMed ID: 1734946
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of cell surface structures involved in cytotoxicity mediated by lymphokine activated killer cells.
Bean P; Agah R; Mazumder A
J Biol Response Mod; 1990 Feb; 9(1):92-7. PubMed ID: 2181073
[TBL] [Abstract][Full Text] [Related]
11. Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells.
Gunji Y; Lewis J; Gorelik E
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):663-72. PubMed ID: 2133246
[TBL] [Abstract][Full Text] [Related]
12. Estradiol and its membrane-impermeable conjugate estradiol-BSA inhibit tamoxifen-stimulated prolactin secretion in incubated rat pituitaries.
Aguilar R; Bellido C; Garrido-Gracia JC; Alonso R; Sánchez-Criado JE
Reproduction; 2006 Apr; 131(4):763-9. PubMed ID: 16595727
[TBL] [Abstract][Full Text] [Related]
13. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
14. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
16. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
Lin TH; Chu TM
Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
20. Effects of Phytolacca acinosa polysaccharides I combined with interleukin-2 on the cytotoxicity of murine splenocytes against tumor cells.
Wang HB; Chen WZ; Bao EJ; Zheng QY; Song HL; Fang J; Xu YX; Chen HS
Yao Xue Xue Bao; 1995; 30(6):401-7. PubMed ID: 7572178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
